Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    January 2024
  1. ZHAO J, Xu N, Zhu S, Nie L, et al
    Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
    Cancer Res. 2024;84:154-167.
    PubMed     Abstract available


    December 2023
  2. MISHRA R, Blinka S, Hsieh AC
    Citron Kinase Is a Druggable Target in Treatment-Resistant Prostate Cancer.
    Cancer Res. 2023;83:4008-4009.
    PubMed     Abstract available


  3. AWAD D, Cao PHA, Pulliam TL, Spradlin M, et al
    Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-0555.
    PubMed     Abstract available


    October 2023
  4. RAWAT C, Ben-Salem S, Singh N, Chauhan G, et al
    Prostate cancer progression relies on the mitotic kinase citron kinase.
    Cancer Res. 2023 Oct 6. doi: 10.1158/0008-5472.CAN-23-0883.
    PubMed     Abstract available


    September 2023
  5. LI Z, Ning K, Zhao D, Zhou Z, et al
    Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling.
    Cancer Res. 2023 Sep 7. doi: 10.1158/0008-5472.CAN-23-0308.
    PubMed     Abstract available


  6. BORDELEAU F
    Using Machine Learning to Predict TP53 Mutation Status and Aggressiveness of Prostate Cancer from Routine Histology Images.
    Cancer Res. 2023;83:2809-2810.
    PubMed     Abstract available


  7. NYQUIST MD, Coleman IM, Lucas JM, Li D, et al
    Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
    Cancer Res. 2023;83:2938-2951.
    PubMed     Abstract available


    August 2023
  8. GALLAHER J, Strobl M, West J, Gatenby R, et al
    Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.
    Cancer Res. 2023;83:2775-2789.
    PubMed     Abstract available


  9. SUN R, Yan B, Li H, Ding D, et al
    Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis.
    Cancer Res. 2023 Aug 1:CAN-23-0285. doi: 10.1158/0008-5472.CAN-23-0285.
    PubMed     Abstract available


    July 2023
  10. LI X, Mu P
    The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer.
    Cancer Res. 2023 Jul 28:CAN-23-2260. doi: 10.1158/0008-5472.CAN-23-2260.
    PubMed     Abstract available


    June 2023
  11. PIZURICA M, Larmuseau M, Van der Eecken K, de Schaetzen van Brienen L, et al
    Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer.
    Cancer Res. 2023 Jun 23:CAN-22-3113. doi: 10.1158/0008-5472.CAN-22-3113.
    PubMed     Abstract available


  12. LUNDBERG A, Zhang M, Aggarwal R, Li H, et al
    The genomic and epigenomic landscape of double-negative metastatic prostate cancer.
    Cancer Res. 2023 Jun 8:CAN-23-0593. doi: 10.1158/0008-5472.CAN-23-0593.
    PubMed     Abstract available


    April 2023
  13. FLOC'H N, Kinkade CW, Kobayashi T, Aytes A, et al
    Editor's Note: Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model.
    Cancer Res. 2023;83:1160.
    PubMed    


  14. OUYANG X, Jessen WJ, Al-Ahmadie H, Serio AM, et al
    Editor's Note: Activator Protein-1 Transcription Factors Are Associated with Progression and Recurrence of Prostate Cancer.
    Cancer Res. 2023;83:1161.
    PubMed    


  15. WANG K, Ma F, Arai S, Wang Y, et al
    WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.
    Cancer Res. 2023;83:1016-1030.
    PubMed     Abstract available


    March 2023
  16. ZHANG X, Cheng L, Gao C, Chen J, et al
    Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-kappaB Activation in T Cells and Suppressing Antitumor Immunity.
    Cancer Res. 2023;83:906-921.
    PubMed     Abstract available


  17. LI M, Liu M, Han W, Wang Z, et al
    LSD1 inhibition disrupts super-enhancer driven oncogenic transcriptional programs in castration-resistant prostate cancer.
    Cancer Res. 2023 Mar 6:CAN-22-2433. doi: 10.1158/0008-5472.CAN-22-2433.
    PubMed     Abstract available


    February 2023
  18. AO J, Shao X, Liu Z, Liu Q, et al
    Stimulated Raman Scattering Microscopy Enables Gleason Scoring of Prostate Core Needle Biopsy by a Convolutional Neural Network.
    Cancer Res. 2023;83:641-651.
    PubMed     Abstract available


  19. ZHANG H, Jin X, Huang H
    Deregulation of SPOP in Cancer.
    Cancer Res. 2023;83:489-499.
    PubMed     Abstract available


  20. BLATTI C, de la Fuente Cedeno J, Gao H, Marin-Goni I, et al
    Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer.
    Cancer Res. 2023 Feb 13:CAN-22-1910. doi: 10.1158/0008-5472.CAN-22-1910.
    PubMed     Abstract available


  21. GALLON J, Rodriguez-Calero A, Benjak A, Akhoundova D, et al
    DNA methylation landscapes of prostate cancer brain metastasis are shaped by early driver genetic alterations.
    Cancer Res. 2023 Feb 7:CAN-22-2236. doi: 10.1158/0008-5472.CAN-22-2236.
    PubMed     Abstract available


    January 2023
  22. PATTERSON JC, Varkaris A, Croucher PJP, Ridinger M, et al
    Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.
    Cancer Res. 2023;83:219-238.
    PubMed     Abstract available


    November 2022
  23. CHOU J, Egusa EA, Wang S, Badura ML, et al
    Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer.
    Cancer Res. 2022 Nov 9. pii: 710533. doi: 10.1158/0008-5472.CAN-22-1433.
    PubMed     Abstract available


  24. WU A, Attard G
    Accidentals of the DNA Symphony.
    Cancer Res. 2022;82:3880-3881.
    PubMed     Abstract available


    October 2022
  25. SJOSTROM M, Zhao SG, Levy S, Zhang M, et al
    The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
    Cancer Res. 2022 Oct 17:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-1123.
    PubMed     Abstract available


    September 2022
  26. WANG J, Ying G, Wang J, Jung Y, et al
    Retraction: Characterization of Phosphoglycerate Kinase-1 Expression of Stromal Cells Derived from Tumor Microenvironment in Prostate Cancer Progression.
    Cancer Res. 2022;82:3405.
    PubMed    


  27. WANG J, Lu Y, Wang J, Koch AE, et al
    Retraction: CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway.
    Cancer Res. 2022;82:3406.
    PubMed    


  28. BHOWMICK S, Bhowmick NA
    RARgamma: The Bone of Contention for Endothelial Cells in Prostate Cancer Metastasis.
    Cancer Res. 2022;82:2975-2976.
    PubMed     Abstract available


  29. LI H, Wang Y, Lin K, Venkadakrishnan VB, et al
    CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.
    Cancer Res. 2022;82:3088-3101.
    PubMed     Abstract available


    July 2022
  30. YU G, Corn PG, Shen PF, Song JH, et al
    Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition.
    Cancer Res. 2022 Jul 8. pii: 706930. doi: 10.1158/0008-5472.CAN-22-0170.
    PubMed     Abstract available


  31. DAVIDSON SM, Schmidt DR, Heyman JE, O'Brien JP, et al
    Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.
    Cancer Res. 2022;82:2403-2416.
    PubMed     Abstract available


    June 2022
  32. SHANGGUAN X, Ma Z, Yu M, Ding J, et al
    Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer.
    Cancer Res. 2022 Jun 29. pii: 705311. doi: 10.1158/0008-5472.CAN-21-3822.
    PubMed     Abstract available


  33. BERCHUCK JE, Adib E, Abou Alaiwi S, Dash AK, et al
    The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response.
    Cancer Res. 2022 Jun 22. pii: 705059. doi: 10.1158/0008-5472.CAN-21-3552.
    PubMed     Abstract available


  34. PATEL R, Ford CA, Rodgers L, Rushworth LK, et al
    Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression.
    Cancer Res. 2022 Jun 8. pii: 704813. doi: 10.1158/0008-5472.CAN-21-1301.
    PubMed     Abstract available


    May 2022
  35. QIN L, Chung YM, Berk M, Naelitz B, et al
    Hypoxia-reoxygenation couples 3betaHSD1 enzyme and cofactor upregulation to facilitate androgen biosynthesis and hormone therapy resistance in prostate cancer.
    Cancer Res. 2022 May 10. pii: 696493. doi: 10.1158/0008-5472.CAN-21-4256.
    PubMed     Abstract available


  36. ABATE-SHEN C, Nunes de Almeida F
    Establishment of the LNCaP Cell Line - The Dawn of an Era for Prostate Cancer Research.
    Cancer Res. 2022;82:1689-1691.
    PubMed     Abstract available


    April 2022
  37. RODRIGUEZ Y, Unno K, Truica MI, Chalmers ZR, et al
    A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer.
    Cancer Res. 2022 Apr 11. pii: 694256. doi: 10.1158/0008-5472.CAN-21-3565.
    PubMed     Abstract available


    March 2022
  38. LI R, Zhu J, Zhong W, Jia Z, et al
    Comprehensive evaluation of machine learning models and gene expression signatures for prostate cancer prognosis using large population cohorts.
    Cancer Res. 2022 Mar 31. pii: 682141. doi: 10.1158/0008-5472.CAN-21-3074.
    PubMed     Abstract available


  39. KARABACAK NM, Zheng Y, Dubash TD, Burr R, et al
    Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.
    Cancer Res. 2022;82:1084-1097.
    PubMed     Abstract available


    February 2022
  40. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    PubMed     Abstract available


  41. IPPOLITO L, Comito G, Parri M, Iozzo M, et al
    Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer.
    Cancer Res. 2022 Feb 8. pii: 0008-5472.CAN-21-0914.
    PubMed     Abstract available


  42. MA F, Arai S, Wang K, Calagua C, et al
    Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1807.
    PubMed     Abstract available


    January 2022
  43. MANDIGO AC, Shafi AA, McCann JJ, Yuan W, et al
    Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.
    Cancer Res. 2022;82:221-234.
    PubMed     Abstract available


    December 2021
  44. JIANG X, Guo S, Wang S, Zhang Y, et al
    EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling.
    Cancer Res. 2021 Dec 28. pii: 0008-5472.CAN-21-2988.
    PubMed     Abstract available


  45. XIE W, Reder NP, Koyuncu CF, Leo P, et al
    Prostate cancer risk stratification via non-destructive 3D pathology with deep learning-assisted gland analysis.
    Cancer Res. 2021 Dec 1. pii: 0008-5472.CAN-21-2843.
    PubMed     Abstract available


  46. HAWLEY JR, Zhou S, Arlidge C, Grillo G, et al
    Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.
    Cancer Res. 2021;81:5833-5848.
    PubMed     Abstract available


    November 2021
  47. JUNG Y, Cackowski FC, Yumoto K, Decker AM, et al
    Correction: CXCL12gamma Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2021;81:5777.
    PubMed    


  48. GIL V, Miranda S, Riisnaes R, Gurel B, et al
    HER3 is an Actionable Target in Advanced Prostate Cancer.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-3360.
    PubMed     Abstract available


  49. GHILDIYAL R, Sawant M, Renganathan A, Mahajan K, et al
    Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance.
    Cancer Res. 2021 Nov 5. pii: 0008-5472.CAN-20-3845.
    PubMed     Abstract available


  50. AL-JANABI H, Lewis CE
    Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer.
    Cancer Res. 2021;81:5399-5400.
    PubMed     Abstract available


    October 2021
  51. KUMAR R, Mendonca J, Owoyemi O, Boyapati K, et al
    Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-20-3607.
    PubMed     Abstract available


    August 2021
  52. BUTLER LM, Mah CY, Machiels J, Vincent AD, et al
    Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
    Cancer Res. 2021 Aug 6. pii: 0008-5472.CAN-20-3863.
    PubMed     Abstract available


    July 2021
  53. LABRECQUE MP, Brown LG, Coleman IM, Lakely B, et al
    RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer.
    Cancer Res. 2021 Jul 26. pii: 0008-5472.CAN-21-0307.
    PubMed     Abstract available


  54. EL-KENAWI A, Dominguez-Viqueira W, Liu M, Awasthi S, et al
    Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-4028.
    PubMed     Abstract available


  55. MAVURA MY, Huang FW
    How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.
    Cancer Res. 2021;81:3764-3765.
    PubMed     Abstract available


  56. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    PubMed     Abstract available


  57. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available


    June 2021
  58. PALLMANN N, Deng K, Livgard M, Tesikova M, et al
    Stress mediated reprogramming of prostate cancer one-carbon cycle drives disease progression.
    Cancer Res. 2021 Jun 28. pii: 0008-5472.CAN-20-3956.
    PubMed     Abstract available


  59. WEI J, Yin L, Li J, Wang J, et al
    Bidirectional Crosstalk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
    Cancer Res. 2021 Jun 24. pii: 0008-5472.CAN-21-0198.
    PubMed     Abstract available


  60. HUANG Z, Tang B, Yang Y, Yang Z, et al
    MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.
    Cancer Res. 2021 Jun 22. pii: 0008-5472.CAN-20-4194.
    PubMed     Abstract available


  61. ENRIQUEZ C, Cancila V, Ferri R, Sulsenti R, et al
    Castration-induced down-regulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer.
    Cancer Res. 2021 Jun 21. pii: 0008-5472.CAN-21-0163.
    PubMed     Abstract available


  62. SENA LA, Denmeade SR
    Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon?
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-21-1392.
    PubMed     Abstract available


    May 2021
  63. OSMULSKI PA, Cunsolo A, Chen M, Qian Y, et al
    Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-3595.
    PubMed     Abstract available


  64. MATSUSHITA M, Fujita K, Hayashi T, Kayama H, et al
    Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling.
    Cancer Res. 2021 May 26. pii: 0008-5472.CAN-20-4090.
    PubMed     Abstract available


  65. MARTINEZ RS, Salji MJ, Rushworth L, Ntala C, et al
    SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-3694.
    PubMed     Abstract available


  66. RAHMAN NIA, Sato A, Tsevelnorov K, Shimizu A, et al
    Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.
    Cancer Res. 2021;81:2318-2331.
    PubMed     Abstract available


  67. LIU Z, Guo C, Das SK, Yu X, et al
    Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
    Cancer Res. 2021;81:2429-2441.
    PubMed     Abstract available


    April 2021
  68. MATTHIAS J, Engelhardt J, Schafer M, Bauder-Wust U, et al
    Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Cancer Res. 2021;81:2234-2245.
    PubMed     Abstract available


  69. LACHANCE J
    Beyond Stamp Collecting: Evolutionary and Functional Genomics Advance Our Understanding of Cancer Biology.
    Cancer Res. 2021;81:1637-1638.
    PubMed     Abstract available


    March 2021
  70. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed     Abstract available


    February 2021
  71. PASCHALIS A, Welti J, Neeb AJ, Yuan W, et al
    JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
    Cancer Res. 2021;81:1087-1100.
    PubMed     Abstract available


  72. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed     Abstract available


    January 2021
  73. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available


  74. SOLEIMANY AP, Kirkpatrick JD, Su S, Dudani JS, et al
    Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer.
    Cancer Res. 2021;81:213-224.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.